News & Media
Follow us on our path to driving innovation for immunocompromised people
Scientific Presentations
PritelivirDemonstrated Superior Lesion Healing with Extended Treatment Compared to Investigator’s Choice for Refractory Herpes Simplex Virus Infection in Immunocompromised PatientsinthePRIOH-1 Phase 3 Trial
Roy F. Chemaly1, Jean-Michel Molina2, KimberlyWorkowski3, Robin Avery4,Yeon JooLee5,6, Karl Peggs7, DionysiosNeofytos8, Michelle Yong9, JoeSasadeusz9, Ryan C. Maves10, Benjamin Gaborit11, Daniel Teschner12, Alma Perez-Rios13, AlexanderBirkmann14, Cynthia Wat14,DilruwanC. Herath14, Alessandra Marini14, BernadetteSurujbally14,Melanie Sumner14,Anna Wald15, GenovefaA.Papanicolaou5,6
ESCMID Global 2026 (poster)
Positive Treatment Response of Pritelivir Achieved in Refractory Herpes Simplex Virus Infections in Immunocompromised Patients, Including Haematopoietic Cell and Solid Organ Transplant Recipients, and Oncology Patients: PRIOH-1 Phase 3 Trial (Abstract: 09485)
Roy F. Chemaly, Karl Peggs, Dionysios Neofytos, Kimberly Workowski, Robin Avery, Yeon Joo Lee, Ryan C. Maves, Oliver Cornely, Jannik Stemler, Daniel Teschner, Michelle Yong, Joe Sasadeusz, Sanjeet Dadwal, Jana Dickter, Alexander Birkmann, Cynthia Wat, Dilruwan C.Herath, Alessandra Marini, Bernadette Surujbally, Melanie Sumner, Genovefa A. Papanicolaou.
ESCMID Global 2026 (presentation)
Pritelivir for Refractory HSV Infections in Immunocompromised Patients: Results of a Phase III Trial
Jean-Michel Molina, Kimberly Workowski, Moti N. Ramgopal, Gary P. Wang, Ryan C. Maves, Stuart H. Cohen, Dahlene N. Fusco, Alma Perez-Rios, Joerg Albrecht, Julien Gras, Alexander Birkmann, Cynthia Wat10, Alessandra Marini10, Dilruwan Chaminda Herath10, Stéphane De Wit
CROI 2026 (presentation)
Pritelivir demonstrated superior efficacy compared to investigator’s choice treatment for refractory herpes simplex virus infections in immunocompromised patients: PRIOH-1, phase 3 safety and efficacy
Genovefa A. Papanicolaou, Robin Avery, Kimberly Workowski, Karl S. Peggs, Yeon Joo Lee, Jean-Michel Molina, Anum Abbas, Alma Perez-Rios, Jana Dickter, Sanjeet Dadwal, Stuart Cohen, Nicolas Issa, Palash Samanta, Alexander Birkmann, Cynthia Wat, Dilruwan Chaminda Herath, Alessandra Marini, Bernadette Surujbally, Melanie Sumner, Anna Wald, Roy Chemaly
TANDEM 2026 (presentation)
Preliminary Results of the First-in-Human Phase 1 Trial of AIC468: A Novel Antisense Oligonucleotide that Targets BK-Virus Transcripts
Susanne Bonsmann, Ashish Soman, Vedran Pavlovic, Bernadette Surujbally, Gnana Oli Rajaraman, Cynthia Wat, Dirk Kropeit
IDWeek 2025 (poster)
Efficacy and safety results from the Phase 2 clinical trial of pritelivir versus foscarnet for treatment of acyclovir-refractory and/or resistant mucocutaneous HSV infections in immunocompromised subjects
Camille N. Kotton, MD; Robin K. Avery, MD; Kimberly Workowski, MD; Princy Kumar, MD; Joerg Albrecht, MD; Pranatharthi Chandrasekar, MD; Mayur Ramesh, MD; Anna Wald, MD; Alexander Birkmann, PhD; Melanie E. Sumner, MSc, Bernadette Surujbally, MSc; Cynthia Wat, MBBS; Roy Chemaly, MD
IDWeek 2025 (presentation)
Pharmacokinetics of AIC468 in Healthy Volunteers from a First-in-Human Phase 1 Clinical Trial: A Novel Antisense Oligonucleotode Targeting BK Virus Transcripts
Susanne Bonsmann, Ashish Soman, Vedran Pavlovic, Bernadette Surujbally, Gnana Oli Rajaraman, Peter Lischka, Cynthia Wat, Dirk Kropeit
WTC 2025 (poster)
Pritelivir for Resistant HSV Infections: Phase 3 Progress and Expanding Therapeutic Horizons
Alexander Birkmann, Alessandra Marini, Melanie Sumner, Cynthia Wat
STIV & HIV World Congress 2025 (poster)
Treatment of Herpes Simplex Encephalitis with the Helicase-Primase Inhibitor Pritelivir in an Immunocompromised Patient
Catherina Lueck, Christina Rautenberg, Alexander Birkmann, Susanne Bonsmann, Alessandra Marini, Melanie Sumner, Thomas Schroeder, Sebastian Voigt
ESCMID 2025 (poster)